Concepedia
3
Publications
115
Citations
H-Index
2022
Active since
Affiliations
UCB Pharma (United States)(Current)
Camil Sayegh is an author at UCB Pharma (United States) specializing in clinical trials, immunology, and autoimmune disease.
Top concepts
MedicineImmunologyRheumatologyClinical TrialsAutoimmune DiseaseRheumatoid Arthritis
Publications per year
2022–2023
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial
Andrew L. Mammen, Anthony A. Amato, Mazen M. Dimachkie et al. · The Lancet Rheumatology · 2023 · 52 citations · Full text
Rheumatology, Autoimmune Disease, Immunology +7
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
Guoqing Tang, Yalan Tang, Ketki Dhamnaskar et al. · Frontiers in Immunology · 2023 · 38 citations · Full text
Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model
Sarah Julien, Douangsone D. Vadysirisack, Camil Sayegh et al. · Biomedicines · 2022 · 25 citations · Full text
Rows per page
1–3 of 3